C16 Globotriaosylceramide (d18:1/16:0) – 500 µg

Brand:
Cayman
CAS:
137896-85-6
Storage:
-20
UN-No:
Non-Hazardous - /

C16 globotriaosylceramide is an endogenous sphingolipid found in mammalian cell membranes that is synthesized from C16 lactosylceramide (Item No. 24352).{38975} C16 globotriaosylceramide acts as a receptor for Shiga toxin in B cell-derived Raji cells and THP-1 monocytes.{39721} It accumulates in endothelial cells, pericytes, vascular smooth muscle cells, renal epithelial cells, dorsal ganglia neuronal cells, and myocardial cells in patients with Fabry disease.{38977} C16 globotriaosylceramide is also upregulated in plasma of patients with ovarian carcinoma compared to those with benign ovarian tumors or uterine fibroids.{39712} [Matreya, LLC. Catalog No. 1528]  

 

Available on backorder

SKU: 24875 - 500 µg Category:

Description

A sphingolipid; acts as a receptor for Shiga toxin in B cell-derived Raji cells and THP-1 monocytes; accumulates in various cells in patients with Fabry disease; upregulated in plasma of patients with ovarian carcinoma compared to those with benign ovarian tumors or uterine fibroids,,


Formal name: N-[(1S,2R,3E)-1-[[(O-α-D-galactopyranosyl-(1→4)-O-β-D-galactopyranosyl-(1→4)-β-D-glucopyranosyl)oxy]methyl]-2-hydroxy-3-heptadecen-1-yl]-hexadecanamide

Synonyms:  ​C16 Ceramide Trihexoside (d18:1/16:0)|Gb3 (d18:1/16:0)

Molecular weight: 1,024.30

CAS: 137896-85-6

Purity: ≥98%

Formulation: A solid


Product Type|Biochemicals|Lipids|Sphingolipids||Research Area|Cancer||Research Area|Endocrinology & Metabolism|Inborn Errors of Metabolism||Research Area|Immunology & Inflammation|Adaptive Immunity||Research Area|Immunology & Inflammation|Innate Immunity||Research Area|Infectious Disease|Bacterial Diseases|Shigellosis||Research Area|Lipid Biochemistry|Sphingolipids